Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 12/20 | 0.52 |
| ▸ | CTSV | O60911 | 11/20 | 0.52 |
| ▸ | CTSS | P25774 | 11/20 | 0.52 |
| ▸ | CTSB | P07858 | 8/20 | 0.52 |
| ▸ | CTSK | P43235 | 8/20 | 0.52 |
| ▸ | PNMT | P11086 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805207 | 1.00 | CTSL (0.52) | CTSLCTSVCTSSCTSBCTSK | |
| SCHEMBL16287362 | 1.00 | CTSL (0.52) | CTSLCTSVCTSSCTSBCTSK | |
| SCHEMBL31369749 | 1.00 | CTSL (0.52) | CTSLCTSVCTSSCTSBCTSK | |
| Hydrochloric Acid SCHEMBL16289133 | 0.98 | CTSL (0.51) | CTSLCTSVCTSSCTSBCTSK | |
| SCHEMBL14898396 | 0.88 | PNMT (0.51) | CTSLCTSVCTSSCTSBCTSK | |
| SCHEMBL14942915 | 0.88 | PNMT (0.51) | CTSLCTSVCTSSCTSBCTSK | |
| SCHEMBL21837394 | 0.85 | TAAR1 (0.51) | MAPK1FOLH1TAAR1 | |
| SCHEMBL21837393 | 0.85 | TAAR1 (0.51) | MAPK1FOLH1TAAR1 | |
| SCHEMBL23901512 | 0.85 | PNMT (0.53) | CTSLCTSVCTSSCTSBCTSK | |
| SCHEMBL11134765 | 0.85 | CTSL (0.50) | CTSLCTSVCTSSCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340916-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-11-06 | — | — | US | disclosed |
| EP-4628592-A1 | PEPTIDE PRODUCTION METHOD COMPRISING STEP FOR TRANSLATING AMINO ACID HAVING OXYGEN ATOM AT SPECIFIC POSITION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-08 | — | — | EP | disclosed |
| US-20250302912-A1 | COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-02 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20250276995-A1 | PRODUCTION METHOD FOR PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-04 | — | — | US | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| EP-4592308-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4166133-B1 | COMPOSITION CONTAINING PEPTIDE COMPOUND AND SURFACTANT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| CN-120202211-A | Cyclic compounds having selective KRAS inhibition over HRAS and NRAS | 中外制药株式会社 | 2025-06-24 | — | — | CN | disclosed |
| EP-4242219-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-13 | — | — | EP | disclosed |
| CN-116507763-A | Peptide synthesis method for inhibiting defects caused by diketopiperazine formation | 中外制药株式会社 | 2023-07-28 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230138226-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-03-30 | — | — | US | disclosed |
| US-11542299-B2 | Method for synthesizing peptide containing N-substituted amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-03 | — | — | US | disclosed |
| WO-2022234852-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| WO-2022234853-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | CTSL 1797/4885CTSV 1882/4885CTSS 2182/4885 |
| US-20250276995-A1 | PRODUCTION METHOD FOR PEPTIDE COMPOUND | VIP, IAPP, QPCT | CTSL 192/4885CTSV 1553/4885CTSS 1657/4885 |
| US-20230138226-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | NPPA, VIP, DNPEP | CTSL 194/4885CTSV 894/4885CTSS 749/4885 |
| US-11542299-B2 | Method for synthesizing peptide containing N-substituted amino acid | NPPA, VIP, DNPEP | CTSL 194/4885CTSV 894/4885CTSS 749/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | CTSL 1797/4885CTSV 1882/4885CTSS 2182/4885 |
| US-20250302912-A1 | COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT | PCTP, CETP, PLTP | CTSL 1186/4885CTSV 2767/4885CTSS 3440/4885 |
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | VIP, DNPEP, HM13 | CTSL 1619/4885CTSV 2766/4885CTSS 3164/4885 |
| US-20250340916-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | AARS1, NSUN3, RNGTT | CTSL 691/4885CTSV 848/4885CTSS 481/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CTSL 120/4885CTSV 295/4885CTSS 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.